Funder: National Institutes of Health

Due Dates: June 18, 2025 (New/Renewal/Resubmission) | October 21, 2025 (New/Renewal/Resubmission) | June 18, 2026 (New/Renewal/Resubmission) | October 21, 2026 (New/Renewal/Resubmission) | June 17, 2027 (New/Renewal/Resubmission) | October 21, 2027 (New/Renewal/Resubmission)

Funding Amounts: Up to $350,000 direct costs per year, max 2 years; typical total award up to $700,000 direct costs.

Summary: Supports rigorous validation of transformative, multi-use platform technologies to accelerate diagnostics and therapeutics for heart, lung, blood, and sleep (HLBS) disorders; clinical trials are not allowed.

Key Information: Projects must focus on enabling technology/platform development (not single-use applications); preliminary feasibility data required; foreign organizations are not eligible to apply.